A., Markwardt, M
In the pooled Phase 3 RECONNECT program (two identically designed double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD), bremelanotide 1.75 mg administered subcutaneously on demand produced statistically significant improvements over placebo on both co-primary endpoints the Female Sexual Function Index Desire Domain and the Female Sexual Distress Scale (Desire/Arousal/Orgasm) Question 13 with P 99% (HPLC, LCMS) Container: Sealed metered nasal spray bottle Documentation: Batch-specific Certificate of Analysis (COA) available Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page
.png)
Symptoms requiring healthcare provider contact include: Rash or erythema spreading beyond the injection site or appearing at distant body locations Persistent or worsening symptoms lasting more than 4 to 5 days Significant pain that interferes with movement or daily function Development of pustules, blisters, or skin breakdown Warmth, increasing redness, or red streaking extending from the injection site (potential cellulitis) Fever, chills, or systemic symptoms accompanying local reactions Recurrent severe reactions at multiple injection sites Signs of possible allergic reaction, including hives, facial swelling, or difficulty breathing Call 911 or seek emergency care immediately for signs of severe allergic reaction such as difficulty breathing, throat tightness, severe dizziness, or widespread hives
Find out if there are any supplements that should be avoided when taking acetaminophen (Tylenol)
For researchers based in Bangkok, 5 Amino-1-MQ 50mg is available with same-day collection